Literature DB >> 3970123

Systemic absorption and cardiovascular effects of phenylephrine eyedrops.

V Kumar, R D Schoenwald, D S Chien, A J Packer, W W Choi.   

Abstract

We studied 24 patients undergoing vitreoretinal surgery to compare the systemic absorption and cardiovascular effects of 2.5% aqueous and 10% viscous ophthalmic solutions of phenylephrine hydrochloride. Plasma levels measured in patients receiving two drops of 10% viscous solution were consistently higher ten, 20, and 60 minutes after instillation (P less than .02). Although the mean systolic and diastolic blood pressure was generally higher with the 10% viscous solution, the difference was not statistically significant. Blood pressure was high in several isolated cases. Because maximum plasma levels are achieved within ten to 20 minutes after topical instillation, phenylephrine eyedrops should be administered under close observation so that if an adverse reaction occurs it can be readily treated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3970123     DOI: 10.1016/0002-9394(85)90229-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  14 in total

1.  Phenylephrine 2.5% and 10% in phacoemulsification under topical anaesthesia: is there an effect on systemic blood pressure?

Authors:  N B Kenawy; M Jabir
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

2.  Effect on mydriasis of modifying the volume of phenylephrine drops.

Authors:  E W Craig; P G Griffiths
Journal:  Br J Ophthalmol       Date:  1991-04       Impact factor: 4.638

3.  Effect of 10% phenylephrine eye drops on systemic blood pressure in normotensive & hypertensive patient.

Authors:  Jagdish Bhatia; Mathew Varghese; Arti Bhatia
Journal:  Oman Med J       Date:  2009-01

4.  Comparative study measuring the dilatory effect of a mydriatic device (Mydriasert(®)) versus topical drops.

Authors:  Manuel Saenz-de-Viteri; Patricia Fernández-Robredo; Elisa de Nova; Elvira Bonet-Farriol; Alfonso L Sabater; Javier Zarranz-Ventura; Josemaria Caire; Luis M Sádaba; Angel Salinas-Alamán; Alfredo García-Layana
Journal:  Int J Ophthalmol       Date:  2013-12-18       Impact factor: 1.779

5.  Ocular phenylephrine 2.5% continues to be dangerous.

Authors:  Nauman Ahmed; Waleed Riad; Abdullah Altorpaq; Abdul Zahoor
Journal:  BMJ Case Rep       Date:  2009-03-02

Review 6.  Non-prescription sympathomimetic agents and hypertension.

Authors:  S S Chua; S I Benrimoj
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

Review 7.  Systemic reactions to ophthalmic drug preparations.

Authors:  F T Fraunfelder; S M Meyer
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

8.  Mental status changes induced by eye drops in dementia of the Alzheimer type.

Authors:  P F Reyes; B A Dwyer; R J Schwartzman; T Sacchetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-01       Impact factor: 10.154

9.  Hemodynamic Changes Associated with Mydriatic Eye Drop Administration in Anesthetized Pediatric Patients.

Authors:  Vittoria Arslan-Carlon; Maria C Walline; Kenneth Seier; Kay See Tan; David H Abramson
Journal:  Ocul Oncol Pathol       Date:  2019-10-30

10.  Use of a new ocular insert versus conventional mydriasis in cataract surgery.

Authors:  C Torrón; P Calvo; O Ruiz-Moreno; J Leciñena; A Pérez-Iñigo
Journal:  Biomed Res Int       Date:  2013-05-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.